Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vir Biotechnology Inc (NQ: VIR ) 7.930 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Vir Biotechnology Inc < Previous 1 2 3 4 5 6 7 8 9 10 Next > Breaking Down Vir Biotechnology: 6 Analysts Share Their Views August 02, 2024 Via Benzinga VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024 August 01, 2024 VIR stock results show that Vir Biotechnology missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. Via InvestorPlace Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark July 26, 2024 On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier. Via Investor's Business Daily 3 Undervalued Biotech Gems With 200%+ Analyst Price Targets July 04, 2024 These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise. Via InvestorPlace Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday? June 05, 2024 Vir Biotechnology reports promising Phase 2 SOLSTICE hepatitis delta trial results, showing high virologic response and ALT normalization rates with tobevibart and elebsiran. Via Benzinga Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday June 05, 2024 Via Benzinga Evaluating Vir Biotechnology: Insights From 5 Financial Analysts May 24, 2024 Via Benzinga Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session June 05, 2024 Via Benzinga Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings) May 07, 2024 Via Benzinga VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024 May 02, 2024 VIR stock results show that Vir Biotechnology beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Assessing Vir Biotechnology: Insights From 5 Financial Analysts March 15, 2024 Via Benzinga Recap: Vir Biotechnology Q4 Earnings February 22, 2024 Via Benzinga Earnings Outlook For Vir Biotechnology February 21, 2024 Via Benzinga JP Morgan Downgrades Vir Biotechnology: Here's What You Need To Know January 29, 2024 Via Benzinga From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires March 19, 2024 These biotech stocks to buy offer a gateway to long-term gains, on the back of groundbreaking healthcare innovations. Via InvestorPlace Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio March 13, 2024 One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses. Via InvestorPlace 3 Highly Rated Biotech Stocks to Buy for 300% Gains February 26, 2024 Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings. Via InvestorPlace Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday February 23, 2024 U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday. Via Benzinga Topics Stocks Exposures US Equities Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session February 23, 2024 Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results. Via Benzinga 3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave February 14, 2024 Explore hidden-gem biotech stocks set for growth in a booming market. Uncover top picks ready to redefine healthcare innovation. Via InvestorPlace HC Wainwright & Co. Maintains Buy Rating for Vir Biotechnology: Here's What You Need To Know January 23, 2024 Via Benzinga Earnings Scheduled For February 22, 2024 February 22, 2024 Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. Via Benzinga COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs December 20, 2023 COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n Via Benzinga Exposures COVID-19 7 Small-Cap Stocks to Buy BEFORE the Year-End Rally November 30, 2023 explore and wager on these top small-cap stocks to buy, poised for significant gains in today's dynamic global economy Via InvestorPlace 3 Bill Gates Stocks to Buy for Billionaire-Like Returns October 27, 2023 Microsoft and Berkshire Hathaway are the two most popular Bill Gates stocks. Investors know these three others far less. Via InvestorPlace 7 Biotech Stocks to Get In Now Before Investors Catch On October 23, 2023 Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them. Via InvestorPlace Earnings Scheduled For November 2, 2023 November 02, 2023 Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million. Via Benzinga Biden's Urgent Action Against Antibiotic-Resistant Bacteria - Allocates $100M to Battle Deadly Superbugs September 27, 2023 U.S. President Joe Biden is set to unveil a $100 million research initiative to tackle the growing threat of drug-resistant bacteria. More than a million people worldwide succumb to infections caused... Via Benzinga Stocks That Hit 52-Week Lows On Thursday September 21, 2023 During the session on Thursday, 461 stocks hit new 52-week lows. Via Benzinga Infectious Disease Player Vir Biotech Has Limited Near Term Upside, Analyst Downgrades September 08, 2023 BofA Securities has downgraded Vir Biotechnology Inc (NASDAQ: VIR) to Neutral from Buy with a price target of $14, Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.